{
    "clinical_study": {
        "@rank": "45450", 
        "brief_summary": {
            "textblock": "OBJECTIVES:\n\n      I.  Evaluate the efficacy of octreotide, a somatostatin octapeptide analog, in decreasing\n      gastrointestinal bleeding in patients with hormone-refractory hereditary hemorrhagic\n      telangiectasia or senile ectasia."
        }, 
        "brief_title": "Phase II Pilot Study of Octreotide, a Somatostatin Octapeptide Analog, for Gastrointestinal Hemorrhage in Hormone-Refractory Hereditary Hemorrhagic Telangiectasia and Senile Ectasia", 
        "condition": [
            "Hereditary Hemorrhagic Telangiectasia", 
            "Ectasia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Dilatation, Pathologic", 
                "Gastrointestinal Hemorrhage", 
                "Telangiectasia, Hereditary Hemorrhagic", 
                "Telangiectasis"
            ]
        }, 
        "detailed_description": {
            "textblock": "PROTOCOL OUTLINE: Patients are treated with subcutaneous injections of octreotide twice a\n      day. The dose is adjusted based on response.\n\n      If there is no requirement for transfusions or intravenous iron for 4 weeks and the\n      hemoglobin is greater than 10 mg/dL, therapy is continued for 1 year. If there is no\n      decrease in bleeding after 10 weeks, the patient is removed from study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "PROTOCOL ENTRY CRITERIA:\n\n        --Disease Characteristics-- Hereditary hemorrhagic telangiectasia or senile ectasia\n        Refractory to or unable to tolerate hormonal therapy, i.e.: Estrogen Progesterone Danazol\n        Gastrointestinal (GI) hemorrhage requiring transfusion within past 3 months Recurrent GI\n        bleeding over more than 1 year At least 4 units packed RBCs transfused within past year OR\n        intravenous iron required more than 4 times within past year No other likely source of\n        hemorrhage determined within past year --Prior/Concurrent Therapy-- Disease\n        hormone-refractory --Patient Characteristics-- No octreotide sensitivity"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": "8", 
        "firstreceived_date": "October 18, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00004327", 
            "org_study_id": "199/11875", 
            "secondary_id": "YALESM-7893"
        }, 
        "intervention": {
            "intervention_name": "octreotide", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Octreotide"
        }, 
        "keyword": [
            "genetic diseases and dysmorphic syndromes", 
            "hematologic disorders", 
            "hereditary hemorrhagic telangiectasia", 
            "rare disease", 
            "senile ectasia"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "overall_official": {
            "affiliation": "Yale University", 
            "last_name": "Joshua R. Korzenik", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00004327"
        }, 
        "source": "Office of Rare Diseases (ORD)", 
        "sponsors": {
            "collaborator": {
                "agency": "Yale University", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "National Center for Research Resources (NCRR)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "January 1995", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2000"
    }, 
    "geocoordinates": {}
}